Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DMV in Relapsed/Refractory Multiple Myeloma
NCT00985907Phase 2Terminated
- Sponsor
- University of California, San Francisco
- Start
- Oct 2004
- Primary completion
- Oct 2008
- Modality
- Modified Peptides, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of pegylated liposomal doxorubicin, melphalan, bortezomib in multiple myeloma (MM), sponsored by University of California, San Francisco. Started Oct 2004; status: terminated.
02
Drugs
pegylated liposomal doxorubicinmelphalanbortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00985907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00985907.